Sarepta Therapeutics CEO Doug Ingram announced Wednesday that he will retire by the end of 2026, citing a “shocking and ...

With a new online resource, Eisai is offering patients and caregivers some direction to help navigate a kidney cancer ...

Viatris has been busy over the last year working to resolve FDA concerns at a critical drug manufacturing plant in India ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 | When BridgeBio presented its quarterly report on Tuesday, it laid out expectations on the potential threat of generic pricing ...

GenEdit is sailing toward the clinic with a new name and fresh funding.  | GenEdit is sailing toward the clinic with a new name and fresh funding. Rebranded as BreezeBio, the biotech has raised $60 ...

Following the release of the first swath of results from a pharma- and he | In developing media plans to reach the GLP-1-interested consumer, audio advertising may represent a “blind spot,” according ...

Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...

Sanofi has kicked off its preparations for the 2026 World Cup by becoming an official backer of Boston’s involvement in the soccer showcase. | Sanofi has kicked off its preparations for the 2026 World ...

AstraZeneca is giving Pascal Soriot a pay raise as the longtime CEO weathered a year of “significant geopolitical uncertainty ...

A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. | A coalition of 15 states is filing a lawsuit against Robert F. Kennedy Jr. and the Centers for Disease Control and ...

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD).